Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

March 2, 2018: By Joan McKenna

Valeant reported Feb. 28 that its 2017 revenues totaled $8.72 billion, a 10 percent decrease from 2016 revenues of $9.67 billion.

The company said its Bausch + Lomb/International segment accounted for 56 percent of total revenues in 2017.

Valeant said its revenue decline was partially offset by higher volumes in the Bausch + Lomb/International segment, primarily the US Consumer Products business, and increased international pricing in the segment.

Bausch + Lomb posted 2017 revenues of $4.87 billion, a drop of 1 percent from 2016 revenues of $4.93 billion.

Bausch + Lomb’s Q4-2017 revenues were $1.23 billion, a decline of 3 percent from Q4-2016 revenues of $1.26 billion.

Valeant said it reduced its debt by more than $4.4 billion in 2017. It also reduced debt repayment requirements through 2020 by more than $10.8 billion since Dec. 31, 2016, and eliminated all long-term debt maturities until 2020 and all mandatory amortization requirements.

CEO Joseph C. Papa called 2017 “a year of strong progress for Valeant.”

The company provided guidance for 2018 of $8.10 billion to $8.30 billion in revenues.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales